Related Experiment Video
Updated: Oct 3, 2025

08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.4K
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer
Antonia Digklia1,2, George Coukos2,3,4, Krisztian Homicsko2,3,4,5
1Department of Oncology, Medical Oncology Service, Lausanne University Hospital, Lausanne, Switzerland.
Abstract:
The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.

